Kalevala Therapeutics received an undisclosed amount of funding to advance its platform for repurposing existing drugs into therapies for underserved rare diseases, including Gaucher disease and Sturge-Weber syndrome.
Kalevala Therapeutics received an undisclosed amount of funding to advance its platform for repurposing existing drugs into therapies for underserved rare diseases, including Gaucher disease and Sturge-Weber syndrome.